{
  "docId": "019de071-1981-7442-94ed-ee285d10f59b",
  "docSlug": "c18efbd116f640ca1060cd96d0c18250",
  "documentTitle": "Alkermes | Results Presentation Deck | 31 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 31,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 20,
  "notes": "The chart is a swimmer plot, a common visualization in oncology clinical trials to show patient-level treatment duration and response.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-1981-7442-94ed-ee285d10f59b/14",
  "deckHref": "/decks/019de071-1981-7442-94ed-ee285d10f59b",
  "deckJsonHref": "/decks/019de071-1981-7442-94ed-ee285d10f59b.json",
  "deckAnchorHref": "/decks/019de071-1981-7442-94ed-ee285d10f59b#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.6,
        "x": 0.05,
        "y": 0.22
      },
      "kind": "chart",
      "text": "Swimmer plot showing time on study for 20 patients",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2b9e0beb-5fec-4ec0-b01f-099a6d96fafd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.87
      },
      "kind": "disclaimer",
      "text": "PD: Progressive disease; PR: Partial response; SD: Stable disease. Discontinued treatment for reasons other than disease progression, scans were continued in the follow-up period, per study protocol. Data cut off March 19, 2021, unless otherwise noted",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eb21967b-2124-40d8-91ba-d5120602c4e3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.25,
        "x": 0.43,
        "y": 0.6
      },
      "kind": "legend",
      "text": "Evaluation of SD, PD, PR, Ongoing, Rollover to Part C, PR awaiting confirmation, PR confirmed",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "37041647-2c9f-44a9-b0b5-e8f3d4404fa1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.28,
        "x": 0.68,
        "y": 0.28
      },
      "kind": "list",
      "text": "Preliminary data (ongoing study): Out of 20 evaluable patients (with >= 1 scans): 2 patients achieved partial response (1 awaiting confirmation), as of May 3rd; Stable disease observed in 10 patients; 12 patients continued on study as of data cut off date",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d96212b8-a11c-41b4-b911-90d8ee464423",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.7,
        "x": 0.05,
        "y": 0.07
      },
      "kind": "title",
      "text": "ARTISTRY-1: IV Nemvaleukin Monotherapy Responses in Renal Cell Carcinoma (RCC) Patients",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e420e00b-6eb2-499b-8956-eff8cd440398",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 21,
      "from": 9,
      "beatId": "d9955255-a32f-40ae-8cd0-621b7a3219ac",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Evidence & Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The presentation provides detailed data on ARTISTRY-1 and ARTISTRY-2 clinical trials",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [
    {
      "to": 21,
      "from": 9,
      "name": "Zoom In",
      "slug": "06-zoom-in",
      "bestFor": "Technical deep-dives, case studies, detailed analysis",
      "matchId": "d7735cef-12ea-4b86-b204-a8c9a7eb598c",
      "evidence": "The presentation provides detailed data on the clinical trials",
      "position": 0,
      "objective": "What are the safety and efficacy results of Nemvaleukin Alfa in ARTISTRY-1 and ARTISTRY-2 trials?",
      "structure": "The Big Picture -> Key Area of Focus -> Specific Detail -> Implication",
      "confidence": 0.8,
      "description": "Start broad, then progressively focus on specific details that prove your point"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}